JP2012501302A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012501302A5 JP2012501302A5 JP2011524221A JP2011524221A JP2012501302A5 JP 2012501302 A5 JP2012501302 A5 JP 2012501302A5 JP 2011524221 A JP2011524221 A JP 2011524221A JP 2011524221 A JP2011524221 A JP 2011524221A JP 2012501302 A5 JP2012501302 A5 JP 2012501302A5
- Authority
- JP
- Japan
- Prior art keywords
- derivative
- pyrrolidino
- stereoisomer
- prodrug
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OKGHUXJLDXCNGS-UHFFFAOYSA-N 1-cyclopropylpyrrolidine Chemical class C1CC1N1CCCC1 OKGHUXJLDXCNGS-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08290822.9 | 2008-09-01 | ||
| EP08290822 | 2008-09-01 | ||
| PCT/EP2009/005654 WO2010022850A1 (en) | 2008-09-01 | 2009-08-05 | Fused pyrrolidino-cyclopropane derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012501302A JP2012501302A (ja) | 2012-01-19 |
| JP2012501302A5 true JP2012501302A5 (enExample) | 2013-01-10 |
| JP5579717B2 JP5579717B2 (ja) | 2014-08-27 |
Family
ID=41095854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011524221A Active JP5579717B2 (ja) | 2008-09-01 | 2009-08-05 | 選択的１１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤としての縮合ピロリジノ−シクロプロパン誘導体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8486964B2 (enExample) |
| EP (1) | EP2321317B1 (enExample) |
| JP (1) | JP5579717B2 (enExample) |
| KR (1) | KR101707580B1 (enExample) |
| CN (1) | CN102137864B (enExample) |
| AR (1) | AR073224A1 (enExample) |
| AU (1) | AU2009287118B9 (enExample) |
| BR (1) | BRPI0918288B1 (enExample) |
| CA (1) | CA2735286C (enExample) |
| EA (1) | EA020238B1 (enExample) |
| ES (1) | ES2531633T3 (enExample) |
| IL (1) | IL211447A (enExample) |
| MX (1) | MX2011002181A (enExample) |
| WO (1) | WO2010022850A1 (enExample) |
| ZA (1) | ZA201102418B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9580422B2 (en) * | 2013-10-22 | 2017-02-28 | Bristol-Myers Squibb Company | Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| MA40759A (fr) | 2014-09-26 | 2017-08-01 | Pfizer | Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation |
| EP3235813A1 (en) | 2016-04-19 | 2017-10-25 | Cidqo 2012, S.L. | Aza-tetra-cyclo derivatives |
| CA3243547A1 (en) * | 2021-12-21 | 2023-06-29 | Corcept Therapeutics Inc | INDAZOLE GLUCOCORTICOID RECEPTOR BICYCLIC ANTAGONISTS |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4088652A (en) * | 1975-07-31 | 1978-05-09 | American Cyanamid Company | Acylazabicyclohexanes |
| AU2003287909A1 (en) * | 2003-01-08 | 2004-08-10 | Mibitech Aps | Electro-therapeutic device and method of electro-therapeutic treatment |
| US7700583B2 (en) | 2003-04-11 | 2010-04-20 | High Point Pharmaceuticals, Llc | 11β-hydroxysteroid dehydrogenase type 1 active compounds |
| EP1615698B1 (en) * | 2003-04-11 | 2010-09-29 | High Point Pharmaceuticals, LLC | New amide derivatives and pharmaceutical use thereof |
| WO2006106423A2 (en) * | 2005-04-07 | 2006-10-12 | Pfizer Inc. | Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase |
| EP1971614A1 (en) * | 2005-11-14 | 2008-09-24 | Probiodrug AG | Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase iv inhibitors |
| GB0625198D0 (en) | 2006-12-18 | 2007-01-24 | Glaxo Group Ltd | Chemical compounds |
-
2009
- 2009-08-05 US US13/061,238 patent/US8486964B2/en active Active
- 2009-08-05 ES ES09777657.9T patent/ES2531633T3/es active Active
- 2009-08-05 MX MX2011002181A patent/MX2011002181A/es active IP Right Grant
- 2009-08-05 EA EA201100419A patent/EA020238B1/ru not_active IP Right Cessation
- 2009-08-05 CA CA2735286A patent/CA2735286C/en active Active
- 2009-08-05 JP JP2011524221A patent/JP5579717B2/ja active Active
- 2009-08-05 KR KR1020117007670A patent/KR101707580B1/ko not_active Expired - Fee Related
- 2009-08-05 WO PCT/EP2009/005654 patent/WO2010022850A1/en not_active Ceased
- 2009-08-05 EP EP09777657.9A patent/EP2321317B1/en active Active
- 2009-08-05 BR BRPI0918288-8A patent/BRPI0918288B1/pt not_active IP Right Cessation
- 2009-08-05 AU AU2009287118A patent/AU2009287118B9/en active Active
- 2009-08-05 CN CN200980134854.6A patent/CN102137864B/zh active Active
- 2009-08-28 AR ARP090103315A patent/AR073224A1/es unknown
-
2011
- 2011-02-27 IL IL211447A patent/IL211447A/en active IP Right Grant
- 2011-03-31 ZA ZA2011/02418A patent/ZA201102418B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2020035I1 (no) | cefiderokol, eventuelt på formen av et farmasøytisk akseptabelt salt eller solvat | |
| NL301284I2 (nl) | Etrasimod, of een farmaceutisch aanvaardbaar zout daarvan, zoals etrasimod arginine | |
| FIC20240039I1 (fi) | Kapivasertibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan muodossa | |
| NL301321I2 (nl) | Delgocitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat daarvan | |
| NO2019042I1 (no) | Talazoparib, eventuelt i form av et farmasøytisk aksepterbart salt | |
| NO2020027I1 (no) | glasdegib, eventuelt i form av et farmasøytisk akseptabelt salt, inkludert maleatsaltet | |
| NO2023047I1 (no) | Cedazuridine, or a pharmaceutically acceptable salt thereof | |
| NO2020037I1 (no) | alpelisib eller et farmasøytisk akseptabelt salt derav | |
| NL301150I2 (nl) | setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301202I2 (nl) | Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline | |
| NO2020038I1 (no) | Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt | |
| NL301049I1 (nl) | Crisaborale, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NO2019024I1 (no) | Brigatinib eller et farmasøytisk akseptabelt salt derav | |
| NO2018016I2 (no) | Niraparib eller et farmasøytisk akseptabelt salt, stereoisomer eller tautomer derav | |
| NO2015014I1 (no) | Paritaprevir, eller et farmasøytisk akseptabelt salt eller ester derav | |
| LTPA2018014I1 (lt) | Farmacinė kompozicija 514 | |
| JP2013014622A5 (enExample) | ||
| NO2017059I1 (no) | ribosiklib eller et farmasøytisk akseptabelt salt derav | |
| NO2016016I2 (no) | Lesinurad, eller et farmasøytisk akseptabelt salt derav | |
| NL300971I2 (nl) | Eravacycline, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| JP2012107057A5 (enExample) | ||
| JP2013514381A5 (enExample) | ||
| NO2015012I2 (no) | Ombitasvir, eller et farmasøytisk akseptabelt salt derav | |
| LT3492069T (lt) | Farmacinės kompozicijos, apimančios geležies oksihidroksidą | |
| EP1984009A4 (en) | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED STABILITY |